EICHOR
● Completed
A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity
Condition: Overweight and Obesity · Sponsor: Amgen
About this study
The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 administered as a single subcutaneous (SC) dose using a liquid drug product in vial compared to a frozen liquid drug product in vial in participants living with overweight or obesity.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (4)
| Anaheim Clinical Trials | Anaheim, California, United States | — |
| Fortrea Clinical Research Unit - Daytona Beach | Daytona Beach, Florida, United States | — |
| Fortrea Clinical Research Unit - Dallas | Dallas, Texas, United States | — |
| Fortrea Clinical Research Unit Inc. - Madison | Madison, Wisconsin, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07717814